Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Latent transforming growth factor beta binding protein 1 (LTBP1) is an extracellular matrix glycoprotein essential for the proper folding, secretion, localization, and activation of TGF-beta isoforms (TGFB1, TGFB2, TGFB3)[6][3][1]. LTBP1 binds covalently to the latent form of TGF-beta and directs its association with the extracellular matrix, where it regulates the growth factor's availability and activation by integrin-mediated mechanical signals and matrix remodeling enzymes[1][3][6]. LTBP1 is not a classical therapeutic target (like a receptor or enzyme) but is implicated in pathological processes such as tissue fibrosis and cancer due to its role in TGF-beta signaling regulation[1][5][6]. Various alternatively spliced isoforms of LTBP1 exist, reflecting a complex regulation and functional diversity[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Latent transforming growth factor beta binding protein 1 (LTBP1).